Belantamab mafodotin
Based on 1 publication(s) in Google Scholar
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity.
For research use only. We do not sell to patients.
- Purity : 99.67%
- CAS No.: 2050232-20-5
- Molecular Weight:149000 (average)
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-109539
Gemtuzumab ozogamicinCD33 Inhibitor -
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-P99349
Loncastuximab tesirineAntibody-Drug Conjugate -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9980
BelantamabAnti-BCMA/TNFRSF17 Monoclonal Antibody -
HY-132254
Sacituzumab govitecanTrop-2 ADC
Publications Citing Use of MedChemExpress (MCE) Belantamab mafodotin
More
Biological Activity
Description
In Vitro
Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2].
Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2].
Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice harbouring OPM2 tumours[2]
-
Dosage:4 mg/kg
-
Administration:IP, twice weekly for 4 doses
-
Result:Signifcantly improves survival compared to vehicle.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2050232-20-5
-
Appearance Liquid
-
Molecular Weight 149000 (average)
-
Color Colorless to light yellow
-
SMILES
[Belantamab mafodotin]
-
Synonyms
GSK2857916; Belantamab mafodotin-blm
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Neoplasia
Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [Abstract]2026 Mar 12:74:101295. PMID: 41825107
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. [Content Brief]
[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Belantamab mafodotin Related Classifications
HY-P3239 Related Classifications
Powered by Bioz